Sonnet BioTherapeutics (SONN) 10-Q2022 Q1 Quarterly report

Filed: 8 Feb 22, 6:49am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: analytical, Australian, call, certainty, clarify, colorectal, complexity, created, earned, exploit, freestanding, GmbH, healthy, irrevocable, issuer, media, modification, Navigo, outlined, perfect, perpetual, principle, Pty, quarter, rendered, resolution, shipping, SonnetBio, stability, Subtopic, upcoming, visibility, written

Removed: acquirer, administered, agent, Aid, Amendment, apply, assumed, attention, average, begin, broad, BTIG, BURG, cancelable, certify, close, commenced, comprised, computer, consisting, contractually, credit, dated, de, decline, deem, demand, depth, discount, diversion, enacted, executed, exercised, expanded, expansion, experienced, experimental, exposed, facilitating, federal, Flexibility, fluctuated, forward, Framework, full, furniture, goal, government, historically, impacted, incurrence, instituted, involving, issuing, leased, leasehold, loan, maturity, mortgage, narrow, Nasdaq, newly, offering, partially, past, Paycheck, penalty, PPP, prepayment, program, promissory, Protection, provision, pushing, recapitalization, recruit, referred, relate, relationship, remained, repaid, request, requiring, restaurant, reverse, SBA, Security, set, settle, settled, small, SONN, space, structure, structured, symbol, terminated, ticker, titled, traded, treated, Tuesday, unconsolidated, unfavorable, unforgiven, unrelated, utility, valuation, viewed, volatile, volatility, volume, warrant, weighted, workflow

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SONN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS

ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Jay Cross, certify that:

	1.	I am the Chief Financial Officer of Sonnet BioTherapeutics Holdings, Inc. (the “Issuer”).

	2.	Attached to this certification is the Quarterly Report on Form 10-Q for the quarter year ended December 31, 2021(the “Report”) filed by the Issuer with the Securities Exchange Commission pursuant to Section 13(a) or 15(d) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), which contains financial statements.

	3.	I hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

	●	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

	●	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Issuer.

February 8, 2022	/s/ Jay Cross
	Jay Cross
	Chief Financial Officer
	(Principal Financial Officer)